For example, attempts to target mutated, upregulated epidermal growth factor receptor (EGFR), the most common genetic aberration associated with malignant glioma and an upstream component of the MAPK pathway, has been largely unsuccessful due to both inherent and acquired resistance. The gene discussed is EGFR; the disease is malignant glioma.